How Tianeptine Helps Researchers Understand Synaptic Function

IMPORTANT DISCLAIMER: This article discusses tianeptine strictly as a research chemical for laboratory use only. Tianeptine is NOT intended for human consumption, self-administration, or any non-research purposes. The information provided is for educational and research purposes only.

Synapses change strength with use, and tianeptine is one of the pharmacological tools preclinical neuroscience groups use to study how. This article summarizes what peer-reviewed laboratory studies report about tianeptine at the synapse, which preparations and concentrations those studies used, and where the evidence stops. Every finding below comes from animal or in vitro work.

Key Points

• Receptor target: tianeptine is a mu-opioid receptor (MOR) agonist, with a reported binding affinity (Ki) of 383 nM at the human receptor.
• Glutamate signaling: in rodent hippocampus it alters AMPA and NMDA receptor currents and increases phosphorylation of the AMPA receptor subunit GluA1.
• Plasticity: in rat and mouse stress models it restored long-term potentiation (LTP) that stress had blocked.
• Structure: in chronically stressed rats it attenuated remodeling of CA3 dendrites.
• Limits: every result is from animal or in vitro work, most of it in stress models. Data on immediate early genes, network oscillations and long-term depression are missing or sparse.

Why Tianeptine Is Used in Synaptic Research

Receptor Pharmacology

From the late 1980s tianeptine was described as an enhancer of serotonin uptake. A 2014 receptor screen changed that picture by identifying it as a mu-opioid receptor agonist (Gassaway et al., 2014). The study reported a binding affinity (Ki) of 383 nM at the human MOR, with half-maximal G protein activation (EC50) at 194 nM for the human receptor and 641 nM for the mouse receptor. Activity at the delta-opioid receptor was far weaker, with a human EC50 of 37.4 µM, roughly 190 times the MOR value. The kappa-opioid receptor did not respond.

A 2017 study in mice found that the behavioral effects of tianeptine require the MOR (Samuels et al., 2017). Han and colleagues (2021) later reported that those effects depend on MORs located on GABAergic interneurons in the hippocampus. That places the opioid mechanism in the same structure where most synaptic work on tianeptine has been done. For the full receptor profile, see our guide to tianeptine's mechanism of action in laboratory research.

Glutamatergic Modulation

Tianeptine also changes how glutamate receptors behave. A 2010 review in Molecular Psychiatry by McEwen and colleagues describes the shift in the literature from a monoamine account of tianeptine to glutamatergic modulation. The primary studies in the next section supply the measurements. For a receptor-by-receptor breakdown, see tianeptine's role in glutamate receptor research.

Key Research Applications in Synaptic Function Studies

Glutamate Receptor Currents and AMPA Receptor Trafficking

3 lines of evidence describe how tianeptine affects excitatory transmission in rodent hippocampus:

• Receptor currents: in chronically stressed rats, recordings at the CA3 commissural/associational synapse showed that stress raised the NMDA receptor share of the excitatory current and that tianeptine normalized the NMDA-to-AMPA ratio (Kole et al., 2002).
• Receptor phosphorylation: in mouse hippocampal slices, tianeptine increased phosphorylation of the AMPA receptor subunit GluA1 at Ser831 and Ser845 and potentiated AMPA receptor responses. The potentiation required the kinases CaMKII and PKA (Szegedi et al., 2011). An earlier mouse study had linked AMPA receptor phosphorylation to tianeptine's actions (Svenningsson et al., 2007).
• Receptor trafficking: in cultured rat hippocampal neurons, tianeptine rapidly reduced the surface diffusion of AMPA receptors. The mechanism was CaMKII-dependent and strengthened binding between the auxiliary subunit stargazin and the scaffold protein PSD-95. In the same study tianeptine prevented corticosterone-induced dispersal of surface AMPA receptors and restored LTP in acutely stressed mice (Zhang et al., 2013).

Long-Term Potentiation Under Stress

LTP is the standard laboratory measure of synaptic strengthening, and stress suppresses it in the rodent paradigms below.

• In anesthetized rats, elevated-platform stress blocked LTP induction in hippocampal CA1. Tianeptine given after the stress rapidly overcame the block without changing baseline excitatory transmission (Shakesby et al., 2002).
• In rats, acute stress impaired LTP in the pathway from hippocampus to prefrontal cortex, and tianeptine reversed the impairment (Rocher et al., 2004).
• After predator stress, tianeptine's effects on plasticity differed between the hippocampus and the basolateral amygdala (Vouimba et al., 2006). Results from one region do not transfer to another.
• Concentration matters. In mouse slices, 10 µM tianeptine enhanced the initial, GluA1-dependent phase of LTP, and 100 µM impaired the later phases (Szegedi et al., 2011).

These studies measured LTP. They do not report long-term depression (LTD) data, so any LTD claim needs its own evidence. Our article on tianeptine in hippocampal neuron studies covers the hippocampal preparations in more detail.

Structural and Cellular Changes in Stress Models

• Dendrites: chronic stress shortens the apical dendrites of CA3 pyramidal neurons in rats. Tianeptine attenuated that remodeling (Watanabe et al., 1992; Magariños et al., 1999).
• Glutamate uptake: chronic restraint stress up-regulated the glial glutamate transporter GLT-1 in rat hippocampus, and tianeptine reversed the increase (Reagan et al., 2004).
• Growth factors: tianeptine increased brain-derived neurotrophic factor (BDNF) expression in the rat amygdala (Reagan et al., 2007). That result is region-specific and should not be generalized to the whole brain.
• Cell proliferation: in stressed tree shrews, tianeptine prevented stress-induced changes in cell proliferation and hippocampal volume (Czéh et al., 2001).

Key Research Findings at a Glance

Each source below is a peer-reviewed primary study.

• Mu-opioid receptor agonist. Ki of 383 nM at the human receptor. Model: receptor binding and G protein activation assays, human and mouse receptors. Source: Gassaway et al., 2014, Translational Psychiatry.
• Behavioral effects require the mu-opioid receptor. Model: mice. Source: Samuels et al., 2017, Neuropsychopharmacology.
• Stress-elevated NMDA-to-AMPA current ratio normalized. Model: chronically stressed rats, CA3 recordings. Source: Kole et al., 2002, European Journal of Neuroscience.
• GluA1 phosphorylation at Ser831 and Ser845 increased. AMPA receptor responses potentiated. Model: mouse hippocampal slices. Source: Szegedi et al., 2011, Neurochemistry International.
• AMPA receptor surface diffusion reduced through CaMKII, stargazin and PSD-95. Model: cultured rat hippocampal neurons, mouse slices. Source: Zhang et al., 2013, Molecular Psychiatry.
• Stress-induced block of LTP overcome. Model: anesthetized rats, hippocampal CA1. Source: Shakesby et al., 2002, Journal of Neuroscience.
• Stress-impaired LTP reversed in the hippocampus to prefrontal cortex pathway. Model: rats. Source: Rocher et al., 2004, Cerebral Cortex.
• Stress-induced remodeling of CA3 dendrites attenuated. Model: chronically stressed rats. Source: Watanabe et al., 1992, European Journal of Pharmacology; Magariños et al., 1999, European Journal of Pharmacology.
• Stress-induced up-regulation of the glutamate transporter GLT-1 reversed. Model: rats, hippocampus. Source: Reagan et al., 2004, PNAS.
• BDNF expression increased. Model: rats, amygdala. Source: Reagan et al., 2007, European Journal of Pharmacology.
• Stress-induced changes in cell proliferation and hippocampal volume prevented. Model: tree shrews. Source: Czéh et al., 2001, PNAS.

Research Methodologies Employing Tianeptine

In Vitro Preparations

The synaptic findings above come from 2 preparation types: acute hippocampal slices and primary hippocampal neuron cultures. Published bath concentrations run from 3 to 100 µM. Zhang et al. applied 10 and 100 µM to cultured rat neurons and 3, 10 and 50 µM to mouse slices, with 10 µM for the LTP experiments. Szegedi et al. reported LTP results at 10 and 100 µM. Those 2 concentrations had different effects on LTP, so run a concentration-response series in your own preparation before fixing a working concentration. Our guide to preparing tianeptine solutions covers stock preparation.

In Vivo Models

A 2-by-2 design (stressed and unstressed animals, each with and without tianeptine) separates the effect of stress from the effect of the test material. All animal work requires approval from an institutional animal care and use committee.

Electrophysiology

• Whole-cell patch-clamp: isolates AMPA and NMDA receptor currents at a defined synapse, as in the CA3 work by Kole et al.
• Field potential recordings: measure LTP across a population of synapses, in slices (Zhang et al.) or in the intact hippocampus (Shakesby et al.).
• Multi-electrode arrays: extend the same measurements to network activity. Peer-reviewed network-level data on tianeptine are sparse, so array results have little published work to compare against.
  
  

Implementing Tianeptine in Your Research Protocol

Controls

• Vehicle control: the same solvent at the same final concentration, without tianeptine.
• Concentration-response series: at least 3 concentrations spanning the published 3 to 100 µM range.
• Time course: acute application and repeated exposure are separate experiments. Record both.
• Mechanism controls: a MOR antagonist tests whether an effect depends on the opioid receptor. Kinase inhibitors test the CaMKII and PKA dependence reported by Szegedi et al.
• Comparator: a characterized AMPA receptor modulator such as aniracetam gives a reference point for AMPA receptor current experiments.

Procedures and Analysis

• Document solution preparation, storage conditions and lot number for every experiment.
• Standardize exposure durations and measurement timepoints.
• Control temperature and pH.
• Replicate in independent experiments and report negative results.
• Match the statistical test to the design and account for variation between animals or cultures.

Handling, Storage and Solubility

Handle tianeptine with gloves, eye protection and a lab coat, weigh powder under local ventilation, and restrict access to trained personnel. Storage and solubility figures differ between published datasheets, so the certificate of analysis (COA) and label for your lot take priority.

• Solid storage: published datasheets for tianeptine sodium (CAS 30123-17-2) give 2 different conditions, -20°C or room temperature with desiccation. The sodium salt takes up moisture from air, so keep containers sealed.
• Solubility: reported values are up to 100 mM in water (about 46 mg/ml), about 10 mg/ml in PBS at pH 7.2, about 10 mg/ml in ethanol, and between 10 mM (about 4.6 mg/ml) and about 20 mg/ml in DMSO.
• Solutions: prepare aqueous solutions fresh. One datasheet advises against storing an aqueous solution for more than 1 day. Another allows storage at -20°C for up to 1 month.

Nordic Chems publishes independent third-party test results for its materials.

Regulatory Status as of October 2026

Tianeptine is not approved by the FDA for any medical use. On July 8, 2026, the DEA published a proposed rule to place tianeptine and its salts in Schedule I of the Controlled Substances Act. The comment period closed on August 7, 2026, and no final rule had been published as of October 13, 2026. If the rule is finalized as proposed, research and chemical analysis with tianeptine would require DEA Schedule I registration.

The proposal also lists 15 states that already control or ban tianeptine. Our state-by-state guide to tianeptine restrictions tracks them. Confirm the rules for your jurisdiction and your institution before ordering or handling this material.

Sourcing Research-Grade Tianeptine

Before ordering, check 4 things:

• A certificate of analysis that carries a batch number and a test date.
• The identity and purity methods used, such as HPLC and mass spectrometry.
• The salt form and CAS number, matched to the form your protocol specifies.
• Labeling that states "For Research Use Only - Not for Human Consumption."

Nordic Chems supplies tianeptine sodium powder (10 g) for preparing custom concentrations, tianeptine sodium capsules with a nominal reference mass of 12.5 mg per unit, and tianeptine sulfate capsules. The full range is listed under tianeptine research materials. If you are choosing between salts, read tianeptine sodium vs. tianeptine sulfate first. For documentation questions, contact our team.

Open Questions

• Immediate early genes: the studies reviewed here do not show that tianeptine induces c-fos or Arc.
• Network activity: effects on oscillations and on excitatory/inhibitory balance are not established in peer-reviewed work. The interneuron finding from Han and colleagues is a starting hypothesis.
• LTD: unmeasured in the studies above.
• Glia: how the GLT-1 result relates to the receptor-level effects is unresolved.

Summary

Peer-reviewed animal and in vitro studies support 3 statements about tianeptine at the synapse. It is a MOR agonist. It alters AMPA and NMDA receptor function in rodent hippocampus through phosphorylation and receptor trafficking. In stress models it restores LTP and limits dendritic remodeling. Claims beyond those need new data. Tianeptine remains a research material for qualified laboratory use only and is not for human consumption.

FAQs

How should research-grade tianeptine and prepared solutions be stored?

Follow the storage statement on the certificate of analysis for your lot. Published datasheets for tianeptine sodium specify either -20°C or room temperature with desiccation for the solid. Prepare aqueous solutions fresh: one datasheet advises against storing them for more than 1 day, and another allows up to 1 month at -20°C.

What concentrations have published in vitro tianeptine studies used?

Published slice and culture studies used 3 to 100 µM. Zhang et al. (2013) applied 10 and 100 µM to cultured rat hippocampal neurons and 3, 10 and 50 µM to mouse hippocampal slices. Szegedi et al. (2011) reported LTP results at 10 and 100 µM. Run a concentration-response series in your own preparation.

How does tianeptine differ from monoamine reuptake inhibitors as a research tool?

Tianeptine has a tricyclic structure, and its documented targets set it apart. It is a mu-opioid receptor agonist (Gassaway et al., 2014) and it modulates AMPA receptor phosphorylation and trafficking in rodent hippocampus. In the study by Szegedi et al. (2011), imipramine did not reproduce tianeptine's effect on AMPA receptor responses.

What is the solubility of tianeptine sodium in common laboratory solvents?

Reported values vary by datasheet: up to 100 mM in water (about 46 mg/ml), about 10 mg/ml in PBS at pH 7.2, about 10 mg/ml in ethanol, and between 10 mM (about 4.6 mg/ml) and about 20 mg/ml in DMSO. Confirm against the documentation for your lot and test at your working concentration.

How quickly do synaptic effects appear in acute exposure experiments?

Published reports describe fast onsets, and no single figure applies across preparations. In mouse slices, GluA1 phosphorylation rose quickly after tianeptine was applied (Szegedi et al., 2011). In cultured neurons the reduction in AMPA receptor surface diffusion was rapid (Zhang et al., 2013). In anesthetized rats tianeptine rapidly overcame a stress-induced block of LTP (Shakesby et al., 2002). Establish onset in your own preparation with a time course.